GlobeNewswire

Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.
17/03/2026
NORCROSS, Ga., March 17, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today [...]
CoRegen, Inc. Publishes Promising New Data Highlighting SRC-3 Engineered Regulatory T Cells as New Immunotherapy Platform
17/03/2026
Peer-reviewed study demonstrates tumor-eradicating activity and durable anti-tumor immunity in multiple preclinical solid tumor models Findings support the potential of SRC-3 gene disrupted regulatory T cells to expand [...]
Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair
17/03/2026
- Humacyte is also pursuing a mechanism for making Symvess available in Israel on a hospital-by-hospital basis in advance of MAA approval - - Preparation is underway for expansion of Symvess into other countries, [...]
Former Peloton and Equinox Design Leader Cecilia Farooqi Joins Noom as Head of Product Design
17/03/2026
Industry veteran with 20 years of design experience in health, fitness and more further strengthens Noom’s product leadership and expertise PRINCETON, N.J., March 17, 2026 (GLOBE NEWSWIRE) -- Noom, the leading behavior [...]
Bionano Announces Two-Fold Increase in OGM Studies Presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
17/03/2026
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) participated in the 2026 American College of Medical Genetics and Genomics Annual Meeting (ACMG), held March 14–18 in Baltimore, Maryland. [...]
Organoid COMMONS Announces Formation of Governing Board, Appointment of Alliance Director, and Announces Open Call for New COMMONS Members
17/03/2026
SEATTLE, March 17, 2026 (GLOBE NEWSWIRE) -- The Organoid COMMONS (Consortium for Organoid Manufacturing, Measurement, Optimization, and Network for Standards) is pleased to announce formal establishment of its first [...]
Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
17/03/2026
PURCHASE, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented [...]
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference
17/03/2026
New data show that blarcamesine completely rescued impaired motor function Biomarker of nerve fiber density of dopaminergic nerve cells indicating fiber regrowth in striatum with blarcamesine New Parkinson’s model of [...]
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
17/03/2026
- First ZEVASKYN ® commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 – - $191.4M in cash, cash equivalents and short-term investments as of December 31, 2025 [...]
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
17/03/2026
Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026 Obtained alignment with FDA and global regulators for planned Phase 3 trial design in patients with DLB [...]
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs
17/03/2026
Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with meaningful downstream commercial revenue potential NEW YORK, March 17, 2026 (GLOBE [...]
Kane Biotech Announces Publication in Frontiers in Antibiotics Highlighting Advancements in Treating Antibiotic Tolerant Biofilms
17/03/2026
WINNIPEG, Manitoba, March 17, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or “Kane”) announces that Frontiers in Antibiotics has published a peer-reviewed article authored by researchers from [...]
Transpire Bio Strengthens its Leadership Team with Appointment of Ewan Livesey as Head of Business Development
17/03/2026
SUNRISE, Fla., March 17, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., a U.S. based, clinical-stage, revenue-generating biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic [...]
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease
17/03/2026
Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal Care Partnership with Alebund Pharmaceuticals to gain exclusive global development and [...]
Fractyl Health to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Updates on March 24, 2026
17/03/2026
BURLINGTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 [...]
Endogenex Announces Publication of REGENT-1 Clinical Study Results in Diabetes, Obesity and Metabolism
17/03/2026
Peer-Reviewed Data Show Durable HbA1c Reduction, Significant Weight Loss, and a Favorable Safety Profile Through 48 Weeks Following a Single Endoscopic Procedure for Type 2 Diabetes MINNEAPOLIS, March 17, 2026 (GLOBE [...]
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
17/03/2026
Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated in H2 2026 Newly [...]
Picard Medical / SynCardia Announce Successful Four-Year Bridge to Transplant with SynCardia Total Artificial Heart Support
17/03/2026
29-year-old patient supported for more than 1,600 days on the SynCardia Total Artificial Heart before receiving a donor heart transplant TUCSON, Ariz., March 17, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE [...]
Vireo Growth Inc. Announces Fourth Quarter 2025 Results
17/03/2026
Q4 GAAP revenue of $104.5 million increased 317.7% year-over-year, driven by recently closed M&A transactions On a pro forma basis, Q4 same store sales increased 22% year-over-year and wholesale revenue increased 55 [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum